Physician profile
Amy L Blumenthal
NPI 1306843719
$992.90
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $165 · 2021: $157.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $156.57 | 2021 | |
| Merck Sharp & Dohme LLC | $84.99 | 2019-2020 | |
| Abbvie INC. | $83.74 | 2019-2020 | |
| Boston Scientific Corporation | $76.35 | 2019 | |
| Novo Nordisk INC | $72.58 | 2019 | |
| Roche Diagnostics Corporation | $65.81 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.25 | 2019-2020 | |
| Astellas Pharma US INC | $39.52 | 2020 | |
| Amag Pharmaceuticals, INC. | $39.47 | 2019 | |
| Pfizer INC. | $36.01 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.96 | 2019 | |
| Eisai INC. | $34.07 | 2019 | |
| Amgen INC. | $29.44 | 2019-2020 | |
| Allergan, INC. | $24.61 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $24.55 | 2019 | |
| Lupin INC. | $22.17 | 2019 | |
| Exeltis, USA INC. | $17.72 | 2019 | |
| Hologic Sales and Service, LLC | $17.23 | 2020 | |
| Coloplast Corp | $14.20 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $13.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.